This episode explores BPC-157, a synthetic peptide derived from gastric juice, and its potential benefits for treating acid reflux and GERD. The host distinguishes between occasional acid reflux, heartburn, and chronic GERD, highlighting the risks of untreated esophageal damage. While animal studies suggest BPC-157 promotes tissue healing, reduces inflammation, and strengthens the gut barrier, human clinical trials remain limited. The discussion concludes that although current evidence is preliminary, BPC-157 shows promise as a future therapeutic option for gastrointestinal issues.